Radiotherapeutic formulations containing 224RA and a method for their production

Abstract

The invention relates to novel radiotherapeutic formulations containing 224Ra and methods for their production. The invention discloses, in particular, radiotherapeutic formulations comprising at least one salt of the isotope 224Ra, which are characterized in that the content of other radionuclides, in particular, the respective content of certain longeval radionuclides does not exceed a specific numerical value in mBq/g. The invention also relates to a method for producing radiotherapeutic formulations of this type, which is characterized by the following steps: after at least one centrifugation of an aqueous suspension of the compound 228Th(OH)4 and optionally after the resuspension of the raw sediment obtained in said centrifugation, the precipitated 228Th(OH)4 sediment is separated. The supernatant solution of a 224Ra salt that has been obtained is subsequently subjected to sterile filtration and is then made up to the required dose. Finally, said solution is sterilized and bottled in ampoules in a manner known per se.

Dependencies are inferred from the claim text.